The Charles Rodolphe Brupbacher Foundation bestowed recently their biennial prize to five young investigators, who contributed to their Scientific Symposium 2015. Jan Pencik received one of these awards for his research on "Aberrant STAT3-ARF signaling targets distinct subgroups of lethal prostate cancer".
Jan Pencik is a PhD student in the research team of Prof. Lukas Kenner and works on the stand alone project "Genetic analysis of the IL-6 signaling pathway in prostate cancer" funded by the Austrian Science Fund (FWF). In his analysis of a mouse model for prostate cancer, he discovered STAT3 and ARF are sensitive prognostic markers to stratify high from low risk PCa patients. This has high clinical relevance, as currently no markers reliably stratify prostate cancer patients into high and low risk groups.
The entire staff of the LBI-CR wishes to congratulate Jan Pencik to his outstanding success. The research now awarded was in part financially supported by the stand alone project P 26011 of the Austrian Science FUnd (FWF) "Genetic Analysis of the IL-6 Signalling pathway in prostate oncogenesis".